Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seres Theraptc (MCRB)

Seres Theraptc (MCRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,647,105
  • Shares Outstanding, K 91,248
  • Annual Sales, $ 34,510 K
  • Annual Income, $ -70,280 K
  • 60-Month Beta 4.60
  • Price/Sales 77.72
  • Price/Cash Flow N/A
  • Price/Book 11.92
Trade MCRB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.26
  • Number of Estimates 5
  • High Estimate -0.20
  • Low Estimate -0.34
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.19 +6.69%
on 10/30/20
38.50 -24.65%
on 11/18/20
-1.20 (-3.97%)
since 10/27/20
3-Month
22.03 +31.68%
on 09/04/20
38.50 -24.65%
on 11/18/20
+4.31 (+17.45%)
since 08/27/20
52-Week
2.52 +1,051.19%
on 03/12/20
38.50 -24.65%
on 11/18/20
+25.11 (+643.85%)
since 11/27/19

Most Recent Stories

More News
Seres Therapeuti Set to Possibly Rebound After Yesterday's Selloff of 2.30%

Seres Therapeuti (NASDAQ:MCRB) traded in a range yesterday that spanned from a low of $29.85 to a high of $30.73. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of...

MCRB : 29.01 (-1.29%)
Seres Therapeuti Has Returned 35.3% Since SmarTrend Recommendation (MCRB)

SmarTrend identified an Uptrend for Seres Therapeuti (NASDAQ:MCRB) on August 10th, 2020 at $25.50. In approximately 3 months, Seres Therapeuti has returned 35.25% as of today's recent price of $34.49....

MCRB : 29.01 (-1.29%)
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences:

MCRB : 29.01 (-1.29%)
Seres Therapeuti Up 35.1% Since SmarTrend Uptrend Call (MCRB)

SmarTrend identified an Uptrend for Seres Therapeuti (NASDAQ:MCRB) on August 10th, 2020 at $25.50. In approximately 3 months, Seres Therapeuti has returned 35.14% as of today's recent price of $34.46....

MCRB : 29.01 (-1.29%)
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -50.00% and -84.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

MCRB : 29.01 (-1.29%)
Seres Therapeutics: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Monday reported a loss of $30.3 million in its third quarter.

MCRB : 29.01 (-1.29%)
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

--- SER-109 anticipated to be first-ever FDA-approved microbiome therapy -

MCRB : 29.01 (-1.29%)
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

--- Program represents Seres' second active clinical program targeting ulcerative colitis, in addition to its ongoing SER-287 Phase 2b study -

MCRB : 29.01 (-1.29%)
Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020

Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and...

MCRB : 29.01 (-1.29%)
Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and...

MCRB : 29.01 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 30.58
1st Resistance Point 29.79
Last Price 29.01
1st Support Level 28.36
2nd Support Level 27.72

See More

52-Week High 38.50
Last Price 29.01
Fibonacci 61.8% 24.76
Fibonacci 50% 20.51
Fibonacci 38.2% 16.26
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar